Health
First in Human Study with Novel Antisense Oligonucleotide – EurekAlert
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.
IMAGE: focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.
view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, August 11, 2020–A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocar…
-
Noosa News23 hours agoItalian Film Festival, Brisbane: All the Details
-
Noosa News19 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News19 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Business20 hours ago16 ASX 200 shares roar to multi-year highs amid new market milestone